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Formulation and pharmaceutical development of quetiapine 
fumarate sustained release matrix tablets using a QbD approach
The main objective of the present study was to apply QbD 
methodology in the development of once-a-day sustained 
release quetiapine tablets. The quality target product pro-
file (QTPP) was defined after the pharmaceutical properties 
and kinetic release of the innovator product, Seroquel XR 
200 mg. For the D-optimal experimental design, the level 
and ratio of matrix forming agents and the type of extra-
granular diluent were chosen as independent inputs, which 
represented critical formulation factors. The critical quality 
attributes (CQAs) studied were the cumulative percentages 
of quetiapine released after certain time intervals. After the 
analysis of the experimental design, optimal formulas and 
the design space were defined. Optimal formulas demon-
strated zero-order release kinetics and a dissolution profile 
similar to the innovator product, with f2 values of 74.53 and 
83.74. It was concluded that the QbD approach allowed fast 
development of sustained release tablets with similar dis-
solution behavior as the innovator product.
Keywords: quality by design, design of experiments, sus-
tained release, hydrophilic matrix, quetiapine
In the past years, the main goal of antipsychotic drug development has been to de-
velop molecules with higher efficacy and fewer side effects usually associated with the 
classic antipsychotic medications. The newly developed agents, called atypical antipsy-
chotics, are successfully used in the treatment of both positive and negative symptoms of 
schizophrenia and are associated with fewer neurological and endocrine side effects com-
pared to older medications (1). Quetiapine is a recently introduced atypical antipsychotic, 
which has an excellent risk/benefit ratio and is indicated as the first-line option for the 
treatment of psychotic disorder manifestations and schizophrenia (2). Quetiapine is avail-
able as fumarate salt in immediate as well as in sustained released formulations, the in-
novative product being Seroquel. The sustained release formulation was introduced sev-
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period of time, ensuring safety and improving the efficacy of the medical treatment as well 
as patient compliance (3).
One of the most popular delivery systems for oral sustained release dosage forms are 
hydrophilic matrix tablets, which are widely accepted because of their biopharmaceutical 
advantages over other types of dosage forms. The reasons behind the popularity of hydro-
philic matrixes are that they offer precise drug release modulation as a result of hydration 
of non-ionic cellulose ethers, cost effectiveness, and the capacity to provide a prolonged 
and constant therapeutic effect (4, 5). Although developing a hydroxypropyl methylcellu-
lose (HPMC) matrix formulation may seem simple, a large number of variables need to be 
considered for a valid formulation with the desired release kinetics. The release rate from 
the matrix is influenced by factors such as polymer type and level, drug dose and solubil-
ity, polymer-drug ratio, diluent type and level, polymer-diluent ratio and porosity of the 
matrix (6). Pharmacokinetic theory suggests that the ideal release of the drug from a sus-
tained release dosage form, without fluctuations of drug levels in blood stream, is the zero 
order profile. In this situation, the drug is released at the same slow rate throughout the 
entire period, and once steady state is achieved, drug concentration is constant as long as 
absorption persists (7, 8). The strategy of blending high and low viscosity grades of HPMC 
has been used before for the development of hydrophilic matrix formulations with zero 
order release profiles and for reducing the drug release variability, providing uniform 
drug levels (9).
Conventional optimization methods where one factor is optimized at a time consti-
tute the main shortcoming, since they do not take into account potential interactions be-
tween factors, which can lead to a failure in identification of the optimal combination. The 
recently proposed Quality by Design (QbD) regulatory initiative represents a highly sys-
tematic approach implementing the Design of Experiments (DoE) for finding the optimal 
product and process characteristics. DoE provides the largest amount of information from 
the least number of experimental runs by systematic variation of the factors and simulta-
neous evaluation of the effects of multiple variables. Quality assurance has changed from 
the need to show that the final product meets predefined specifications to a new situation 
where it needs to be demonstrated that the product is controlled within a well-defined 
design space (10, 11). The design space is defined as an established multidimensional range 
of input variables (e.g., formulation factors) and process parameters demonstrated to provide 
assurance of quality (12).
Use of in vitro drug dissolution values as DoE output variables has been recognized 
as an important strategy for drug development. Drug release from immediate and sus-
tained oral dosage forms is described by several kinetic equations. Interpretation of output 
variables representing in vitro release values is realized with the help of mathematical 
polynomial equations that convert the dissolution profiles into parameters relating to the 
pharmaceutical characteristics of the dosage form (13, 14).
The aim of this study was to apply a QbD approach in order to develop once-a-day 
sustained release 200-mg quetiapine tablets. A quadratic D-optimal experimental design 
was used to evaluate the effect of matrix-forming polymer (HPMC) percentage and filler 
type on the cumulative ratio of drug released at different time intervals for a period of 24 
hours, and to define the optimal formulations. The optimization procedure would help 
define the design space and set up formulation parameters for the preparation of con-
trolled release tablets with predictable properties.
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Quetiapine fumarate was purchased from Menadiona, Spain. Lactose monohydrate 
– Pharmatose 150M (DFE Pharma, Germany) was used as a diluent and polyvinylpyrrol-
idone – Kollidon 30 (BASF, Germany) as a binder in the granulation step. Two types of 
HPMC with different viscosity grades – Methocel K100 Premium LV CR and K4M Premi-
um CR (Colorcon, United Kingdom) were used as matrix-forming excipients. Lactose 
monohydrate – Tablettose 80 (Meggle, Germany), microcrystalline cellulose – Avicel PH102 
(FMC BioPolymer, USA), fumed silica – Aerosil 200 (Röhm, Germany) and magnesium 
stearate – Kemilub EM-F (Undesa, Spain) were used as extragranular excipients.
QbD steps
The first step in a QbD type study is to define the Quality Target Product Profile 
(QTPP) and to identify the potential Critical Quality Attributes (CQAs) based on it. QTPP 
was defined by the International Conference on Harmonization (ICH) Q8 as „a prospec-
tive summary of the quality characteristics of a drug product that ideally will be achieved 
to ensure the desired quality, taking into account safety and efficacy of the drug product” 
(15) and it represents the basis for the design of a generic product (16). The QTPP was set 
based on literature specifications for sustained release oral tablets and on the results ob-
tained after analyzing the innovative quetiapine extended release product, Seroquel XR. 
The developed product should contain 200 mg quetiapine that will be released from a 
hydrophilic matrix over 24 hours, similarly to the innovator product. According to the 
European Pharmacopeia specifications, the tablets should be free of any visual defects, the 
quetiapine identification should be positive and the active pharmaceutical ingredient 
(API) content variation should not exceed 5 %. The mass of the tablets should be uniform, 
with variations under 5 %, friability should be under 1 % (m/m) and the crushing resistance 
over 150 N in order to assure tablet integrity (17). The dissolution profile should be similar 
to the profile of the innovator product; in this way, similar absorption kinetics should be 
achieved by controlling the kinetic drug release from the dosage form.
Also, according to the ICH Q8, the CQA is „a quality attribute (a physical, chemical, 
biological or microbiological property of characteristic) that must be controlled (directly or 
indirectly) to ensure that the product meets its intended safety, efficacy, stability and per-
formance” (15). The most significant CQAs that need to be considered in the pharmaceuti-
cal development of sustained release formulations are the dissolution release profile and 
kinetic drug release. According to the literature, the levels of matrix forming agents and 
the type of extragranular diluent are the potential risk factors that might influence the 
CQAs of a sustained release formulation; this is the reason why these factors were chosen 
as variables in this study.
Experimental design
To be able to understand the product and refine the formulation of sustained release 
hydrophilic matrix tablets, we have chosen to use a full factorial D-optimal experimental 
design with one qualitative and two quantitative factors and five levels, using Modde 11.0 
software (Umetrics, Sweden).
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Preliminary studies were performed to select the starting formulations, and it was 
observed that the desired kinetic release profile could only be obtained by using a combi-
nation of two matrix forming excipients with different viscosities. In the formulation, the 
main matrix forming excipient used was Methocel K100, blended in various proportions 
with a higher viscosity polymer, Methocel K4M. In the DoE, the first chosen formulation 
factor was the total percent of matrix forming excipient, the second quantitative factor be-
ing the proportion of Methocel K4M to the total quantity of matrix forming excipient used 
for each formulation. The selected qualitative factor was the type of extragranular diluent. 
The responses studied were the cumulative percentages of quetiapine released at different 
time intervals. The levels of variation for the independent and dependent variables are 
presented in Table I. The effects of independent variables over the measured responses 
were evaluated by the analysis of coefficients and contour plots. Based on these results, the 
design space and optimal formulations were calculated by the Modde software.
In general, the experimental design region defined in the QbD approach illustrates the 
whole range of interactions between the chosen inputs and the studied responses, whereas 
the design space is defined by ICH Q8 as „the multidimensional combination and interaction 





Total HPMC (%) X1 30 45
HPMC K4M from the total HPMC (%) X2 0 50





Dependent variables (responses) CQAs
Minimum Target Maximum
Cumulative % of quetiapine released after 1 h Y1 3 5 7
Cumulative % of quetiapine released after 2 h Y2 6 10 12
Cumulative % of quetiapine released after 3 h Y3 10 14 17
Cumulative % of quetiapine released after 4 h Y4 14 18 22
Cumulative % of quetiapine released after 6 h Y5 23 28 33
Cumulative % of quetiapine released after 8 h Y6 32 36 43
Cumulative % of quetiapine released after 10 h Y7 41 46 53
Cumulative % of quetiapine released after 12 h Y8 50 56 62
Cumulative % of quetiapine released after 18 h Y9 70 79 85
Cumulative % of quetiapine released after 24 h Y10 84 93 100
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of input variables that have been demonstrated to provide assurance of quality” (15). In 
regulatory terms, changes inside the design space do not need to be considered as changes, 
only changes outside this space should initiate post approval procedures (18). Further in this 
direction, a proven acceptable range (PAR) was defined inside the design space. The PAR is 
explained by ICH Q8 as „a characterized range of a process parameter for which operation 
within this range, while keeping other parameters constant, will result in producing a mate-
rial meeting relevant quality criteria” (15). This acceptable range is defined by a design space 
hypercube, which represents the largest possible regular hypercube that can be inserted into 
the irregular design space and shows the volume in which all factor combinations can be 
used without compromising the product’s CQAs (19). After the determination of the design 
space and PAR, the optimal formulations were determined by defining combinations of fac-
tor values that predict a result as close as possible to the target values of all responses (20).
Tablet preparation
In order to obtain good quality hydrophilic matrix tablets, a preliminary granulation 
step was required; the formulation of the granules and the granulation parameters were 
established during preliminary studies (data not shown). Quetiapine fumarate (82 %) and 
lactose monohydrate (15 %) were granulated in an Aeromatic Strea 1 fluidized bed granu-
lator (GEA, Switzerland) using a polyvinylpyrrolidone solution (3 %) as binding agent. A 
quantity of granules corresponding to 200 mg of quetiapine/tablet unit was subsequently 
mixed for 5 minutes in a polyethylene bag together with the extragranular excipients. The 
formulation is given in Table II. Tablets were compressed from the mixes using an eccentric 
tablet press (Korsch EK-0, Germany) equipped with a 13 mm, round, flat and plain punch. 
The compressing machine was adjusted so that the manufactured tablets had an average 
weight of ~ 640 mg and a crushing strength greater than 50 N.
Tablet evaluation
Standard evaluation tests specified for tablets in the European Pharmacopoeia were 
performed (17). Mass variation was determined by weighting 20 tablets individually, the 
Table II. Formulation of the hydrophilic matrix tablets
Ingredient Percent in formulation (%)
Quantity for a single tablet 
(mg)
Quetiapine fumarate granulate 44.7 286.1
HPMC K100 30–45 96–288
HPMC K4M 0–22,5 0–144
Lactose monohydrate / Microcrystalline 
cellulose 9.3–24.3 59.5–155.5
Fumed silica 0.5 3.20
Magnesium stearate 0.5 3.20
Total 100 640
58
A. Gavan et al.: Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD 
approach, Acta Pharm. 67 (2017) 53–70.
 
average mass was calculated and percent of variation was calculated. Hardness was eval-
uated on 6 tablets from each series using a Dr. Schleuniger Pharmaton 6D hardness tester 
(Pharmaton, Switzerland) and friability was evaluated on 10 tablets using an Erweka TA10 
friabilator (Erweka, Germany) set at 100 rotations.
In vitro dissolution studies for the developed tablets, containing 200 mg quetiapine, were 
performed using a PharmaTest PTWS 100 dissolution tester (PharmaTest, Germany) applying 
the basket method (European Pharmacopoeia apparatus 1) at 100 rpm in 900 mL 0.05 mol L–1 
phosphate buffer pH 6.8, maintained at 37 ± 0.5 °C. 5 mL samples were withdrawn through 
10 µm cannula filters at 1, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h. In order to maintain a constant volume 
throughout the experiment, each taken sample was replaced with the same volume of fresh 
medium. Dissolution studies were run in triplicate for each formula and the absorbance was 
measured on 1:5 diluted samples at 246 nm using a Specord 200 Plus UV/Vis Spectrophotom-
eter (Analytik Jena, Germany). Cumulative drug release was calculated using an equation 
determined from Lambert Beer’s calibration curve in the linearity range of 0–50 µg mL–1. For 
each sampling point, mean and standard deviations were calculated.
Release kinetics
To evaluate the release profiles of the formulations, several release profiles were test-
ed, such as zero order, first order (21, 22), Higuchi (23), Hixon-Crowell (24) and Korsmeyer-
Peppas (25). Mathematical models were fitted one at a time to individual dissolution data, 
using the SigmaPlot 11.0 (Systat software, USA) software. For each model, regression anal-
yses were applied to obtain the release constant k, correlation coefficient R2 and the Akaike 
Information Criterion (AIC). The use of AIC helped compare the competing models; a 
lower value of this criterion means a better model fit.
RESULTS AND DISCUSSIONS
Preparation and evaluation of tablet formulations
All the batches were produced under similar conditions to avoid processing vari-
ables and the hydrophilic matrix tablets from each batch were analyzed according to the 
European Pharmacopoeia methods for average mass, mass uniformity, crushing resis-
tance and friability (17). According to the obtained results, all prepared formulations had 
an average mass of 640 ± 7 mg with the intra-batch weight variability lower than 1.9 %. 
The tablets showed a high crushing resistance between 50 and 180 N and very low friabil-
ity under 1 %.
Thus, all the tablet batches demonstrated very good pharmaceutical properties, which 
complied with the European Pharmacopoeia requirements, proving that the different pro-
portions of hydrophilic polymers and diluents used in the formulations did not influence 
the uniform filling of the dyes during the tableting step.
CQAs of sustained release formulations
Critical Quality Attributes (CQAs) are physical, chemical, biological, or microbiologi-
cal properties or characteristics that should be within an appropriate limit, range, or dis-
59
A. Gavan et al.: Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD 
approach, Acta Pharm. 67 (2017) 53–70.
 
Table III. Experimental design matrix of factors and responses
Experiment code X1 X2 X3 Y1 Y2 Y3
N1 30 0 lactose 11 21 31
N2 45 0 lactose 6 13 20
N3 30 50 lactose 9 16 22
N4 45 50 lactose 5 8 12
N5 30 33.3 lactose 9 16 23
N6 45 16.7 lactose 6 11 17
N7 35 0 lactose 11 21 30
N8 40 50 lactose 4 8 12
N9 37.5 25 lactose 7 13 19
N10 30 0 cellulose 10 18 27
N11 45 0 cellulose 6 13 19
N12 30 50 cellulose 8 13 17
N13 45 50 cellulose 5 8 11
N14 30 16.7 cellulose 11 18 24
N15 45 33.3 cellulose 4 8 12
N16 40 0 cellulose 8 14 21
N17 35 50 cellulose 6 10 14
N18 37.5 25 cellulose 8 13 18
N19 37.5 25 cellulose 6 11 16
N20 37.5 25 cellulose 6 11 16
Y4 Y5 Y6 Y7 Y8 Y9 Y10
N1 40 58 72 82 90 90 90
N2 26 38 50 60 69 88 89
N3 28 39 47 53 60 77 87
N4 16 23 30 34 39 52 62
N5 30 44 54 64 73 91 98
N6 23 34 43 54 63 82 94
N7 37 52 64 76 85 95 97
N8 15 23 29 35 40 54 66
N9 25 35 44 51 58 80 93
N10 35 49 62 72 83 91 92
N11 25 37 47 58 66 87 93
N12 21 29 34 39 44 57 67
N13 14 20 25 28 31 43 52
N14 30 40 48 55 62 84 95
N15 17 24 31 38 43 57 71
N16 28 40 51 61 69 90 97
N17 17 24 31 36 40 52 62
N18 23 33 42 49 57 78 96
N19 21 30 39 46 54 74 90
N20 21 30 39 46 53 72 90
X1–X3 – independent variables (factors) according to Table II.
Y1–Y10 – dependent variables (responses), according to Table II.
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tribution to ensure the desired product quality, the values that need to be well controlled 
in order to ensure the efficacy and performance of the designed product (15).
In order to rapidly define a formulation with similar release kinetics as the target 
product profile, the D-optimal experimental design was applied. After preliminary stud-
ies and based on the literature, it was established that the following formulation factors 
would have the main role in assuring the correct kinetic drug release from the hydro-
philic matrix, the amount and proportion of HPMC and the type of extragranular diluent. 
Therefore, the studied critical formulation factors were the total percent of HPMC (X1), 
proportion of the high viscosity HPMC used, reported to the total quantity of matrix form-
ing excipient (X2) and the type of extragranular diluent (X3). For an extended release for-
mulation, the most significant parameters that assure the product performance and effi-
cacy are the dissolution profile defined by cumulative percentages of the drug released at 
different time intervals. Thus, the responses of the experimental design, namely, cumula-
tive percentages of the drug released at different time intervals (Y1 to Y10), were established 
as CQAs. The accepted intervals for the CQAs were calculated considering the dissolution 
profile of the innovative product Seroquel XR and are presented in Table I.
Experimental design analysis. Summary of fit
The experimental design matrix generated by the Modde software and completed 
with the responses obtained after performing all experimental runs is shown in Table III. 
The results show that the kinetic release of quetiapine was influenced by the formulation 
factors studied in the experimental design.
The multiple linear regression (MLR) fitting of the experimental data with the ex-
perimental design was evaluated using the following statistical parameters: R2, Q2 and 
ANOVA test. R2 represents the goodness of fit and describes the fraction of variation of the 
response explained by the model, while Q2 represents the goodness of prediction and esti-
mates the prediction capacities of the model. The values of R2 and Q2 are between 0 and 1; 
for a model to pass the diagnostic test, both parameters should have high values indicating 
a good model with very high predictive power. The difference between the two should be 
no more than 0.2–0.3, higher differences indicating an inappropriately selected model. 
Together, R2 and Q2 are the most reliable statistical parameters to describe the validity of 
a model (26).
A summary of fit plot was generated for all responses obtained after fitting and statis-
tical parameter calculation using the data obtained from the experimental design. The 
selected model showed excellent quality, responses from Y2 to Y10 had values of over 0.93 
for R2, over 0.86 for Q2. Slightly lower, but still excellent, values were registered for Y1 (R2 
of around 0.87 and Q2 of 0.73).
Another important diagnostic test for model validity is the ANOVA test (analysis of 
variance), which shows whether the variance of the results is determined by modifications 
in the formulation factors or represents a variance determined by experimental errors (26). 
For all dependent variables, the p values of the ANOVA test were lower than 0.001 for the 
model and greater than 0.31 for the lack of fit. These results show that the quadratic mod-
el is statistically good, implying a significant influence of the factors on the responses, and 
that the model has no lack of fit.
61
A. Gavan et al.: Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD 
approach, Acta Pharm. 67 (2017) 53–70.
 
Experimental design analysis. Evaluation of variables affecting kinetic drug release
The in vitro release data over 24 hours of quetiapine from the developed hydrophilic 
matrix tablets at different dissolution time intervals are displayed in Table III. The MLR 
fitting of the experimental data and the regression coefficients were determined using the 
following equation:
 Yn = b0 + b1X1 + b2X2 + b3X3 + b13X1X3 + b22X22  (Eq. 1)
where Yn is the dependent variable; b0 is the model constant; b1, b2, b3 are linear coefficients; 
b13 is an interaction coefficient between two factors; b22 is a quadratic coefficient and X1, X2, 
X3 are the coded levels of independent variables. The equation coefficients used to fit the 
data to the quadratic model represent the influence of the studied factors and of the inter-
actions between factors on the responses.
Two and three dimensional plots were formed, based on the model, for evaluation of 
the responses, in order to assess the change of the response surface. Also, the relationship 
between formulation factors (independent variables) and responses (dependent variables) 
can be further understood from these plots (19, 27).
The influence of formulation factors on the most relevant responses (Y2, Y4, Y6, Y8, Y9 
and Y10) is presented as scaled and centered coefficients in Figure 1 and as the response 
surface plot in Figure 2 (a, b), for the formulations with lactose as diluent (N1–N9) and for 
the formulations with cellulose as extragranular diluent (N10–N20), respectively. The 
same tendencies regarding the influence of formulation factors were found for the other 
responses analyzed in the experimental design (Y1, Y3, Y5, and Y7). Results of the coefficient 
data analysis indicate that the amount of the matrix forming agent (X1) and the proportion 
of Methocel K4M blended with Methocel K100 (X2) had the most significant influence on 
drug release.For this type of formulation, erosion is the principal mechanism of drug re-
lease and the blending of two polymers with different viscosities was an alternative to 
obtain a hydrophilic matrix that allowed the desired extended drug release over 24 hours. 
In the developed formulations, the main component of the matrix forming polymer was 
the low-viscosity grade HPMC, which helped maintain a consistent erosion of the matrix, 
allowing a constant drug release over the whole desired period of time. This effect is 
shown in the coefficient plot by the relative constant negative value of the coefficient of X1 
(values between 3.5 and 8) at all dissolution points (Fig. 1). Consistent erosion of the matrix 
assured by this polymer is represented on the contour plots by the linear relationship be-
tween the coefficient of X1 and the responses, observed over the whole period of time 
studied (Fig. 2). Addition of the higher viscosity polymer, Methocel K4M, increased the gel 
strength and assured integrity of the matrix over a longer period of time. This means that 
drug release decreases with an increase of the amount of high viscosity polymer (9). The 
effect is also described by the evolution of the coefficient plot; influence of the coefficient 
factor X2 increases with time, being smaller in the first hours and growing with time. In 
this case, the existence of the X2*X2 term must be indicated, which is insignificant in the 
first 12 hours of the dissolution (Y2 to Y8), but its intensity increases sharply for the last two 
dissolution points, after 18 and 24 hours, respectively (Y9 and Y10), points at which it has a 
significant influence on the responses. The same phenomenon is displayed on the contour 
plot, the relationship between factor X2 and the responses Y2 to Y8 is linear, but becomes 
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Fig. 1. Influence of formulation factors on the in vitro drug release at different dissolution time points, 
presented as scaled and centered coefficient plots. X1 – total HPMC percent; X2 – HPMC K4M propor-
tion of the total HPMC percent; X3 – type of extragranular diluent (lactose, cellulose); Y2, Y4, Y6, Y8, 
Y9, Y10 – dependent variables according to Table II.
non-linear in the second half of the dissolution period, indicating the quadratic nature of 
the relationship between factor X2 and the responses Y9 or Y10.
The difference in drug release between formulations containing lactose monohydrate 
and microcrystalline cellulose as extragranular diluents can be mainly attributed to the 
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differences in solubility of the two excipients. Lactose will dissolve and will increase water 
availability within the gel structure of the hydrophilic matrix, favoring a diffusion mech-
anism besides the main erosion mechanism and in this way increasing drug release (28). 
On the other hand, microcrystalline cellulose will slow down the release of the active 
substance. This can be explained by the fact that, in the added proportions (10–25 %), cel-
lulose has some binding properties that will harden the tablet and slow down matrix ero-
sion (29). The two studied diluents influence drug release in opposite directions, but with 
approximately equal intensities. Their influence increases gradually and becomes constant 
after the first 4 hours of the dissolution. No significant interactions were registered be-
tween the studied formulation factors; the quality of the model was enhanced if these 
coefficients were discarded.
Design space and formulation optimization
In order to obtain a sustained release dosage form with constant drug release over 24 
hours, the experimental formulations were compared with the dissolution profile of the 
original controlled release dosage form available on the market, namely, Seroquel XR 200 
mg. The release profile of the reference dosage form was analyzed and the QTPP was estab-
lished. From the initial investigation domain, a design space was identified, where all the 
CQAs specifications should be fulfilled. Using the design space explorer function from the 
optimization module of the Modde software, the design space shown in Fig. 3 was devel-
oped by applying a series of limitations indicated in Table I, setting the CQAs to either a 
minimum or a maximum. Given that one input was qualitative (the type of extragranular 
Fig. 2. Influence of formulation factors on the in vitro drug release at different dissolution time points 
for formulations with: a) lactose monohydrate and b) microcrystalline cellulose as diluents, repre-
sented as contour plots. X1 – total HPMC percent; X2 – HPMC K4M proportion of the total HPMC 
percent; Y2, Y4, Y6, Y8, Y9, Y10 – dependent variables according to Table II.
a)                                                                              b)   
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diluent), two design spaces were generated, one for each variable. The green area represents 
the design space and each point from this area predicts, with a low probability of failure 
under 1 %, a possible hydrophilic matrix formulation that would possess the described 
CQAs (20). The dotted frame inside the design space is the design space hypercube, which 
defines the proven acceptable range (PAR). Within this area, factor values can vary indepen-
dently from each other, while the obtained product will meet the specified quality target. 
The cross-hairs that can be noticed in the figures indicate the robust setpoint, representing 
the input values that will predict, with the highest statistical values, a result within specifi-
cations. The main difference between robust and optimal setpoints is that the optimal set-
point is focused on finding a solution as close to the target as possible (19).
Robust setpoints and hypercube edges for the two design spaces can be seen in Fig. 3; 
the calculated setpoint values were X1 = 43.06, X2 = 29.03 for the formulation with lactose 
as extragranular diluent, and X1 = 42.58, X2 = 22.58 for the formulation with microcrystal-
line cellulose as extragranular diluent. By analyzing Fig. 3, it can be noticed that both the 
design space and the PAR are wider when using cellulose as extragranular diluent.
The following step was to use the optimization module of the software to identify 
optimal formulation factors based on CQAs. The levels of these factors, as well as the pre-
dicted and the obtained experimental dissolution values are shown in the first part of 
Table IV. Optimal formulations were performed and analyzed under the same conditions 
as all other experimental formulations and the obtained experimental values were very 
close to the theoretical ones, predicted by the experimental design.
To confirm the validity of the calculated model, a negative formulation (X1 = 30, X2 = 
10 X3 = microcrystalline cellulose) with values outside the design space was prepared and 
Fig. 3. The design space and proven acceptable range (PAR) for the hydrophilic matrix formulations 
with: a) lactose monohydrate and b) microcrystalline cellulose as diluents. X1 – total HPMC percent; 
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evaluated. The developed design space and the dissolution profile of all the validation 
formulations and of Seroquel XR are illustrated in Fig. 4. It is noticeable that the drug is 
released faster from the negative formulation, with different kinetics than from Seroquel 
XR, all intermediate dissolution points being outside the design space, while both ideal 
formulations have all the dissolution points inside the design space, very close to the op-
timal values.
One way to compare the dissolution profile of the developed formulations and the 
original product was to calculate and analyze the release kinetics. As shown in the second 
part of Table IV, the kinetic drug release of Seroquel XR was best described by a Peppas 
model. The two optimal formulations had very similar release kinetics to the reference 
product, but were better described by zero order kinetics. The strategy of using a blend of 
high and low viscosity grades of HPMC has been reported before in order to achieve a zero 
order release profile from a matrix formulation and for reducing the variability of drug 
release (30, 31).
For evaluation of the similarities between dissolution profiles of the developed formu-
lations and the original product, the similarity factor f2 was used. In order to consider the 
two compared profiles as similar, the value of this factor needs to be greater than 50 (32). 
For the two optimal formulations, no significant differences in dissolution profiles were 
observed, the values registered for f2 being 83.74 for the lactose formulation and 74.53 for 
the formulation developed with cellulose as diluent. On the other hand, the negative for-
mulation failed the similarity test, registering an f2 value of 49.82.
Thus, by choosing adequately the critical formulation factors as independent vari-
ables of the experimental design and using the optimization module of the Modde 11.0 
software, the theoretical optimal formulations of sustained release tablets were deter-
mined with great accuracy.
Fig. 4. Dissolution profiles of the negative and the two optimal formulations compared to Seroquel XR.
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However, according to the recent studies of Kulinowski et al. (33, 34), in order to com-
pletely understand the hydrating process of the matrix and the release mechanisms, it 
would be essential to distinguish between the two key factors, namely the biopharmaceu-
tical characteristics of the sustained release dosage form and the intrinsic properties of the 
matrix. The in vitro dissolution test offers valuable information regarding the biopharma-
ceutical properties of the sustained release dosage form and allows a good description of 
these characteristics, but can only deliver an indirect and incomplete characterization of 
the intrinsic physicochemical, structural and morphological matrix properties. In order to 
completely understand and assess the internal properties of the hydrophilic matrix, ap-
plication of complementary techniques such as magnetic resonance imaging or micro-CT 
would be highly recommended.
CONCLUSIONS
The QbD approach has been used in this study as a strategy for the design of a sus-
tained release tablet formulation, with a desired in vitro drug release behavior, in order to 
minimize the fluctuations of drug level in the blood stream, maintain the therapeutic 
level of the active substance in the blood, improve drug efficacy, increase patient compli-
ance and lower the risk of side effects. Use of DoE software enabled the development and 
evaluation of hydrophilic matrix type sustained release formulations, as well as the obser-
vation of formulation related variable effects on the selected responses. Both studied quan-
titative factors proved to have important influences on the kinetic release profiles of the 
tablets.
The design space and optimal formulations were defined taking the drug release ki-
netics of Seroquel XR™ 200 mg as a model. Three optimized formulations (two inside and 
one outside the design space) were tested in order to validate the model. The obtained re-
sults were in good accord with the predicted values, the dissolution profiles of the valida-
tion samples being similar to the targeted dissolution profile.
This study has proven that the QbD approach allows quick finding of a formulation 
having a dissolution profile similar to the innovative product, using a D-optimal experi-
mental design to analyze the influence of formulation factors on the in vitro dissolution 
behavior.
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